SCHEMBL352798

SCHEMBL352798

CCC(=O)Oc1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.69
PKM P14618 1/20 0.52
PBRM1 Q86U86 1/20 0.51
MAPT P10636 4/20 0.50
KDM4E B2RXH2 2/20 0.50
APAF1 O14727 1/20 0.50
POLB P06746 1/20 0.50
RECQL P46063 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
ALOX5 P09917 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28113890 0.98 SLC22A6 (0.67) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL20481507 0.89 SLC22A6 (0.55) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL148210 0.89 SLC22A6 (0.67) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL28215558 0.88 SLC22A6 (0.65) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL17536618 0.88 SLC22A6 (0.65) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL28021733 0.88 SLC22A6 (0.65) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL6835665 0.87 SLC22A6 (0.68) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL1714417 0.87 SLC22A6 (0.68) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL3446433 0.85 SLC22A6 (0.66) SLC22A6PKMPBRM1MAPTKDM4E
SCHEMBL10599504 0.85 SLC22A6 (0.61) SLC22A6PKMPBRM1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12633376-B2 System and method for risk assessment of autism spectrum disorder TATA CONSULTANCY SERVICES LIMITED (IN) 2026-05-19 US claimed
US-20260053887-A1 Methods and Kits to Prevent And/Or Treat Cardiac Disorders UNIV IOWA RES FOUND (US) 2026-02-26 US claimed
US-20250367246-A1 IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES SOLAREA BIO INC (US) 2025-12-04 US claimed
US-20250356948-A1 SYSTEM AND METHOD FOR RISK ASSESSMENT OF AUTISM SPECTRUM DISORDER TATA CONSULTANCY SERVICES LIMITED (IN) 2025-11-20 US claimed
US-12440523-B2 Immunomodulatory compositions comprising microbial entities SOLAREA BIO, INC. (US) 2025-10-14 US claimed
CN-119951426-A Double-network gel microsphere with pH response and preparation method and application thereof 合肥工业大学 2025-05-09 CN claimed
CN-118931933-A Recombinant vector for biosynthesis of indopropionic acid, engineering bacterium and application thereof 镇江市天益生物科技有限公司 2024-11-12 CN claimed
EP-4452287-A2 IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIES Solarea Bio, Inc. (US) 2024-10-30 EP claimed
CN-118831071-A Sequential multistage targeted delivery system for repairing intestinal barrier and preparation method thereof 大连理工大学 2024-10-25 CN claimed
CN-118696825-A Liaodong clove immature embryo regeneration method 青海省农林科学院 2024-09-27 CN claimed
US-20050197253-A1 Methods for improving growth and crop productivity of plants by adjusting plant hormone levels, ratios and/or co-factors BANK OF AMERICA, NA 2005-09-08 US claimed
WO-2005021715-A2 METHODS FOR IMPROVING GROWTH AND CROP PRODUCTIVITY OF PLANTS BY ADJUSTING PLANT HORMONE LEVELS, RATIOS AND/OR CO-FACTORS STOLLER ENTERPRISES, INC. (US) 2005-03-10 WO claimed
WO-2005018319-A2 SUPPRESSING PLANT PATHOGENS AND PESTS WITH APPLIED OR INDUCED AUXINS STOLLER ENTERPRISES, INC. (US) 2005-03-03 WO claimed
US-20050043177-A1 Controlling plant pathogens and pests with applied or induced auxins BANK OF AMERICA, NA 2005-02-24 US claimed
EP-1372571-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS New Century Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds NEW CENTURY PHARMACEUTICALS, INC. 2002-12-19 US claimed
WO-2002074246-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS NEW CENTURY PHARMACEUTICALS, INC. (US) 2002-09-26 WO claimed
EP-1171603-A1 A PROCESS FOR PRODUCING PURIFIED BIOLOGICALLY ACTIVE, FREE FORM OF RECOMBINANT HUMAN INTERFERON GAMMA Vyas, Sharad Kumar (IN) 2002-01-16 EP claimed
WO-2001057218-A1 A PROCESS FOR PRODUCING PURIFIED BIOLOGICALLY ACTIVE, FREE FORM OF RECOMBINANT HUMAN INTERFERON GAMMA VYAS SHARAD KUMAR (IN) 2001-08-09 WO claimed
EP-0175577-A2 Microchemiluminescent assay system Kiel, Jonathan L (US) 1986-03-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12633376-B2 System and method for risk assessment of autism spectrum disorder TPH1, KYNU, TPH2 SLC22A6 1288/4885PKM 674/4885PBRM1 1388/4885
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds ALB, TYMP, SHBG SLC22A6 588/4885PKM 4433/4885PBRM1 4366/4885
US-20260053887-A1 Methods and Kits to Prevent And/Or Treat Cardiac Disorders KYNU, AADAT, TPH1 SLC22A6 891/4885PKM 1234/4885PBRM1 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.